Research progress on MCL-1 and its inhibitors in hematological malignancies
10.3969/j.issn.1000-8179.2017.11.301
- VernacularTitle:MCL-1及其抑制剂在血液恶性肿瘤靶向治疗中的研究进展
- Author:
Bei SUN
- Keywords:
MCL-1;
apoptosis;
BH3 mimetics;
hematological malignancies;
targeted therapy
- From:
Chinese Journal of Clinical Oncology
2017;44(11):562-566
- CountryChina
- Language:Chinese
-
Abstract:
Myeloid cell leukemia-1 (MCL-1) protein is one of the key antiapoptotic protein members of the B-cell lymphoma-2 protein family. Overexpression of MCL-1 is closely related to not only tumor progression but also resistance to targeted therapy and traditional chemotherapeutic drug. MCL-1 and its inhibitors have been studied in recent years. The mimetics of MCL-1 endogenous ligand BH3 have resulted in significant breakthroughs. In this study, the research progress on MCL-1 and its inhibitors in hematological malignan-cies is reviewed.
